Health & Fitness
Health and Fitness
Health and Fitness
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009 Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study on February 5, 2009
DANBURY, Conn.--([ BUSINESS WIRE ])--Biodel Inc. (Nasdaq: BIOD) will issue its fiscal first quarter 2009 financial results on February 5, 2009. The company will also discuss the top line results of its study testing the bioequivalence of the 25 IU two part formulation and 100 IU one part liquid formulation of VIAject(TM) in patients with Type 1 diabetes. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
February 5, 2009 schedule:
| 4:00 pm EST: | Q1 fiscal 2009 results will be | ||||||||
| distributed by Business Wire | |||||||||
| 4:50 pm EST: | Conference call participants should dial: | ||||||||
| +1 877-857-6161 (United States) or | |||||||||
| +1 719-325-4802 (International) | |||||||||
| 5:00 pm EST: | Conference call begins |
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at [ http://www.biodel.com ]. The audio webcast will be archived and available for replay through the website.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed using VIAdelTM technology, which reformulates existing FDA-approved peptide drugs. For further information regarding Biodel, please visit the company's website at [ www.Biodel.com ].
BIOD-G
